Acalabrutinib
Details of the Drug
- Generic Name:
- Acalabrutinib
- Pronunciation:
- Not available
- Drug Type:
- BTK inhibitor
- How the Drug is Given:
By mouth
- Names:
- Calquence®
- Acalabrutinib
Indications and Usage
Acalabrutinib is a kinase inhibitor indicated:
- In combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation (HSCT).
- For the treatment of adult patients with MCL who have received at least one prior therapy.
- For the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Side effects needing medical attention
Headache, diarrhea, bruising, fatigue and muscle pain (myalgia), and reduced levels of red blood cells (anemia), platelets (thrombocytopenia) and neutrophils (neutropenia) in the blood.
Serious side effects include bleeding (hemorrhage), infections and irregular heartbeat (atrial fibrillation). Additional cancers, known as second primary malignancies, have occurred in some patients taking Calquence.
For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.